

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

FOR THE MONTH OF MARCH 2026

COMMISSION FILE NUMBER 001-39081

BioNTech SE

(Translation of registrant's name into English)

**An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On March 10, 2026, BioNTech SE (the “Company”) issued a press release announcing its full year 2025 financial results and corporate update and details of a conference call to be held at 8:00 am EDT on March 10, 2026 to discuss the results. The press release and the conference call presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein.

The information contained in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By: /s/ Ramon Zapata-Gomez
Name: Ramon Zapata-Gomez
Title: Chief Financial Officer

By: /s/ Dr. Sierk Poetting
Name: Dr. Sierk Poetting
Title: Chief Operating Officer

Date: March 10, 2026

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
99.2	Fourth Quarter and Full Year 2025: Financial Results and Corporate Update

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

- **BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies**
- **Increased focus on PD-L1/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb**
- **Full year 2025 revenues of €2.9 billion², net loss of €1.1 billion (adjusted³ net loss of €0.1 billion) and diluted loss per share of €4.70 (\$5.31⁴) (adjusted³ diluted loss per share of €0.48 (\$0.55⁴))**
- **Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion⁵**
- **Expect 2026 total revenues of €2.0 billion to €2.3 billion, adjusted³ R&D expenses between €2.2-2.5 billion and adjusted³ SG&A expenses⁷ between €700-800 million**
- **BioNTech co-founders Ugur Sahin and Özlem Türeci to establish an independent company with a focus on next-generation mRNA innovations; management transition by end of 2026**

Conference call and webcast scheduled for March 10, 2026, at 8:00 a.m. EDT (1:00 p.m. CET)

MAINZ, Germany, March 10, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today reported financial results for the three months and full year ended December 31, 2025 and provided an update on its corporate progress.

"2025 was a year of strong execution and pipeline momentum, marked by substantial progress in delivering on our strategy. We advanced our oncology pipeline by moving multiple programs into late-stage development and initiated trials assessing novel-novel combination approaches with the aim of delivering differentiated therapeutic profiles," said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. "With our unique pipeline and strong financial position, we remain committed to leveraging our pioneering position in the immuno-oncology space with next-generation agents designed to elevate outcomes for patients with cancer. 2026 is poised to be a pivotal year with multiple readouts expected across our portfolio, representing a significant step toward our objective of becoming a multi-product company by 2030."

Financial Review for Fourth Quarter and Full Year 2025³

in millions €, except per share data	Full Year 2025		Full Year 2024	
	IFRS Results	Adjusted Results ³	IFRS Results	Adjusted Results ³
Revenues	2,869.9	2,869.9	2,751.1	2,751.1
Net profit / (loss)	(1,136.1)	(117.1)	(665.3)	121.7
Diluted earnings / (loss) per share	(4.70)	(0.48)	(2.77)	0.50

in millions €,
except per share data

	Fourth Quarter 2025		Fourth Quarter 2024	
	IFRS Results	Adjusted Results ³	IFRS Results	Adjusted Results ³
Revenues	907.4	907.4	1,190.0	1,190.0
Net profit / (loss)	(305.0)	(79.5)	259.5	432.4
Diluted earnings / (loss) per share	(1.25)	(0.33)	1.08	1.79

Revenues for the three months ended December 31, 2025, were €907.4 million, compared to €1,190.0 million for the comparative prior year period. For the year ended December 31, 2025, revenues were €2,869.9 million, compared to €2,751.1 million for the comparative prior year period. The quarterly year-on-year decrease was primarily driven by lower sales of the Company's COVID-19 vaccines due to reduced market demand. The full year revenue increase was primarily driven by revenues related to BioNTech's collaboration with Bristol Myers Squibb Company ("BMS") that were recognized in the third quarter of 2025.

Research and development ("R&D") expenses were €505.4 million for the three months ended December 31, 2025, compared to €611.8 million for the comparative prior year period. For the year ended December 31, 2025, R&D expenses were €2,104.9 million, compared to €2,254.2 million for the comparative prior year period. Both quarterly and full year year-on-year decreases were mainly driven by cost savings resulting from active portfolio management and positive effects resulting from our pumitamidg cost sharing with BMS, partly offset by the acceleration of late-stage trials for immuno-oncology ("IO") and antibody-drug conjugate ("ADC") development programs.

Adjusted R&D expenses were €505.4 million for the three months ended December 31, 2025, compared to €530.3 million for the comparative prior year period. For the year ended December 31, 2025, adjusted R&D expenses were €2,019.5 million, compared to €2,172.7 million for the comparative prior year period. For 2025 and 2024, the Company's adjusted R&D expenses exclude impairments.

Sales, general and administrative ("SG&A") expenses⁷ were €217.9 million for the three months ended December 31, 2025, compared to €132.1 million for the comparative prior year period. For the year ended December 31, 2025, SG&A expenses were €624.4 million, compared to €599.0 million for the comparative prior year period. Both quarterly and full year year-on-year increases were mainly driven by our ongoing commercial build-up, partly offset by lower costs for external services.

Other operating result was negative €173.6 million during the three months ended December 31, 2025, compared to negative €54.0 million for the comparative prior year period. For the year ended December 31, 2025, other operating result was negative €903.7 million compared to negative €670.9 million for the prior year period. Both quarterly and full year year-on-year decreases were primarily driven by expenses from settlements of contractual disputes, expenses in connection with our pipeline prioritization and foreign exchange differences.

Adjusted other operating result was €21.4 million during the three months ended December 31, 2025, compared to negative €1.6 million for the comparative prior year period. For the year ended December 31, 2025, other operating result was negative €0.6 million compared to negative €13.5 million for the prior year period. For fiscal years 2025 and 2024, our quarterly and full year adjusted other operating results exclude expenses in connection with the settlements of legal proceedings. In addition, our quarterly and full year adjusted other operating results during fiscal year 2025 exclude employee-related costs in connection with our pipeline prioritization and a bargain purchase.

Net loss was €305.0 million for the three months ended December 31, 2025, compared to a net income of €259.5 million for the comparative prior year period. For the year ended December 31,

2025, net loss was €1,136.1 million, compared to a net loss of €665.3 million for the comparative prior year period.

Adjusted net loss was €79.5 million for the three months ended December 31, 2025, compared to an adjusted net profit of €432.4 million for the comparative prior year period. For the year ended December 31, 2025, adjusted net loss was €117.1 million, compared to an adjusted net profit of €121.7 million for the comparative prior year period.

Diluted loss per share was €1.25 for the three months ended December 31, 2025, compared to diluted earnings per share of €1.08 for the comparative prior year period. For the year ended December 31, 2025, diluted loss per share was €4.70, compared to diluted loss per share of €2.77 for the comparative prior year period.

Adjusted diluted loss per share was €0.33 for the three months ended December 31, 2025, compared to adjusted diluted earnings per share of €1.79 for the comparative prior year period. For the year ended December 31, 2025, adjusted diluted loss per share was €0.48, compared to adjusted diluted earnings per share of €0.50 for the comparative prior year period.

Cash, cash equivalents and security investments as of December 31, 2025, were €17,235.6 million, comprising €7,675.4 million in cash and cash equivalents, €7,158.5 million in current security investments disclosed as financial assets and €2,401.7 million in non-current security investments disclosed as financial assets.

Shares outstanding as of December 31, 2025, were 251,325,340, excluding 7,702,147 shares held in treasury.

“Our strong financial position fuels and de-risks our R&D activities as we prepare for multiple product launches in the coming years. Our financial discipline, active portfolio management and targeted investments will continue to drive innovation and create long-term value for BioNTech’s stakeholders,” **said Ramón Zapata, Chief Financial Officer at BioNTech.**

2026 Financial Year Guidance⁶:

Revenues for the 2026 financial year	€2,000 – €2,300 m
---	--------------------------

In 2026, BioNTech anticipates lower COVID-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets. The United States continues to be a competitive and dynamic market, where as a result, lower revenues are expected. In Europe, we expect lower revenues as we defend our market share and begin managing the transition of multi-year contracts. In Germany, specifically, BioNTech recognizes direct sales of its COVID-19 vaccines as revenue. Hence, the anticipated declines in the Company’s sales of COVID-19 vaccines in the country will have a direct impact on its topline, whereas revenues outside of Germany only affect the Company’s topline as part of the 50% gross profit split with our partner Pfizer Inc. (“Pfizer”). Per the outlined partnership terms, revenues from the collaboration with BMS in 2026 are expected to be broadly in line with 2025. Revenues from the pandemic preparedness contract with the German government and service businesses are expected to remain stable.

Planned 2026 Financial Year Adjusted Expenses⁶:

Adjusted R&D expenses	€2,200 – €2,500 m
Adjusted SG&A expenses	€700 – €800 m

BioNTech will continue to focus investments on R&D and scaling the business for late-stage development and commercial readiness in oncology, while remaining cost-disciplined. Strategic capital allocation will continue to foster innovation and be a key driver of the Company's trajectory. As part of BioNTech's strategy, the Company may continue to evaluate appropriate corporate development opportunities with the aim of driving sustainable long-term growth and creating future value.

The full audited consolidated financial statements as of and for the year ended December 31, 2025, can be found in BioNTech's Annual Report on Form 20-F filed today with the U.S. Securities and Exchange Commission ("SEC") and available at www.sec.gov.

Endnotes

¹ An overview of abbreviations is compiled in a directory at the end of this press release.

² All numbers in this press release have been rounded.

³ In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found at the end of this press release and in BioNTech's Report on Form 20-F for the year ended December 31, 2025 filed on March 10, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards.

⁴ Calculated applying the average foreign exchange rate for the year ended December 31, 2025, as published by the German Central Bank (Deutsche Bundesbank).

⁵ As of December 31, 2025.

⁶ Excludes risks that are not yet known and/or quantifiable and related activities. It includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions ("M&A") transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech's Report on Form 20-F for the year ended December 31, 2025 filed on March 10, 2026, which is available at www.sec.gov.

⁷ Sales, general and administrative expenses ("SG&A") include sales and marketing expenses as well as general and administrative expenses. Adjusted SG&A expenses include adjusted sales and marketing expenses as well as adjusted general and administrative expenses.

Operational Review for the Fourth Quarter and Full Year 2025, Key Post Period-End Events and Outlook on 2026**Corporate Update for the Fourth Quarter 2025 and Post Period Events**

- On March 10, 2026, BioNTech announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Özlem Türeci, M.D. The new company with distinct resources, operations and funding options will advance next-generation mRNA innovations. BioNTech plans to contribute related rights and mRNA technologies to the new company to enable and support the prioritized development of next-generation mRNA innovations with disruptive potential. With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike. Ugur Sahin and Özlem Türeci will transition into the management of their new company by the end of 2026 after their current service agreements end. BioNTech's Supervisory Board has initiated an executive search to identify successors for the positions to ensure a smooth transition and seamless execution of BioNTech's strategy.
- On March 1, Kylie Jimenez joined BioNTech's Management Board as Chief People Officer ("CPO"). The appointment is in line with BioNTech's strategy to become a multi-product

biopharmaceutical company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. Kylie will focus on attracting, developing and retaining talent, while strengthening an inclusive culture.

Select Oncology Pipeline Updates

Next-Generation Immunomodulators and Combinations

Pumitamig (BNT327/BMS986545) is a bispecific immunomodulator candidate combining PD-L1 checkpoint inhibition with VEGF-A neutralization that is being developed in collaboration with BMS.

- A global Phase 3 clinical trial in patients with first-line triple-negative breast cancer ("TNBC") (ROSETTA Breast-01; [NCT07173751](#)) is enrolling.
- A global Phase 2/3 clinical trial to evaluate pumitamig in first-line microsatellite stable colorectal cancer ("CRC") (ROSETTA CRC-203; [NCT07221357](#)) is enrolling.
- A global Phase 2/3 clinical trial to evaluate pumitamig in first-line gastric cancer (ROSETTA Gastric-204; [NCT07221149](#)) is enrolling.
- A global Phase 2/3 clinical trial (ROSETTA Lung-02; [NCT06712316](#)) is ongoing to evaluate pumitamig in combination with chemotherapy compared to pembrolizumab and chemotherapy in patients with first-line non-small cell lung cancer ("NSCLC"). The Phase 2 part of the seamless Phase 2/3 trial achieved full enrollment and the Phase 3 portion is currently recruiting. Data from the Phase 2 part of the trial are expected in 2026.
- Additional pivotal Phase 2/3 and Phase 3 trials are planned to start in 2026, in unresectable stage III NSCLC (ROSETTA Lung-201, [NCT07361497](#)), first-line PD-L1 \geq 50% NSCLC (ROSETTA Lung-202, [NCT07361510](#)) and first-line head and neck squamous cell carcinoma ("HNSCC") (ROSETTA HNSCC-205).
- Pumitamig is also being evaluated in additional solid tumor indications, including first-line hepatocellular carcinoma ("HCC"), second-line glioblastoma ("GBM"), first-line pancreatic ductal adenocarcinoma ("PDAC") and first-line renal cell carcinoma ("RCC") in various Phase 1/2 and Phase 2 trials, both as monotherapy and in combination with standard of care.
- In 2025, BioNTech initiated several signal-seeking clinical trials to evaluate pumitamig with the Company's proprietary assets. These trials will inform the dose selection for pumitamig and explore anti-tumor activity in multiple tumors for later-stage development.

Gotistobart (BNT316/ONC-392) is a tumor microenvironment-selective regulatory T cell depletion candidate that targets CTLA-4 and is being developed in collaboration with OncoC4, Inc. ("OncoC4").

- A global Phase 3 clinical trial (PRESERVE-003; [NCT05671510](#)) is ongoing to evaluate the efficacy and safety of gotistobart as monotherapy in patients with metastatic squamous NSCLC ("sqNSCLC") that progressed under previous platinum-based chemotherapy and PD-(L)1-inhibitor treatment.
- In December 2025, data from the non-pivotal dose-confirmation stage, the first of two stages of the global Phase 3 clinical trial, were presented at the International Association for the Study of Lung Cancer ("IASLC") American Society of Clinical Oncology ("ASCO") 2025 North America Conference on Lung Cancer ("NACLC"). Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard of care chemotherapy and a manageable safety profile in patients with squamous NSCLC whose disease had progressed following anti-PD-(L)1 therapy and platinum-based chemotherapy.

- Based on current event accrual projections, interim data from the pivotal stage of the two-stage Phase 3 clinical trial are expected in 2026.
- In January 2026, gotistobart received Orphan Drug Designation from the U.S. Food and Drug Administration ("FDA") for the treatment of squamous NSCLC. In 2022, gotistobart received Fast Track Designation from the FDA for the treatment of patients with metastatic NSCLC whose disease progressed on prior anti-PD-(L)1 therapy.

Antibody-Drug Conjugates

Trastuzumab pamirtecan (BNT323/DB-1303) is an ADC candidate targeting HER2 that is being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. ("DualityBio").

- A Phase 1/2 clinical trial ([NCT05150691](#)) is ongoing to evaluate trastuzumab pamirtecan in patients with advanced HER2-expressing tumors. A potentially registrational cohort with HER2-expressing (IHC3+, 2+, 1+ or ISH-positive) patients with recurrent endometrial cancer is ongoing. Data are expected to be shared at a medical conference in 2026. BioNTech and DualityBio plan to file a biologics license application ("BLA") in 2026, subject to regulatory feedback from the FDA.
- A global Phase 3 clinical trial (DYNASTY-Breast02, [NCT06018337](#)) to evaluate trastuzumab pamirtecan in patients with HR-positive, HER2-low metastatic breast cancer is ongoing. Based on current event accrual projections, data are expected in 2026.

BNT324/DB-1311 is an ADC candidate targeting B7H3 that is being developed in collaboration with DualityBio.

- In February 2026, updated data from a Phase 1/2 clinical trial ([NCT05914116](#)) were presented at the ASCO Genitourinary Cancers Symposium. BNT324/DB-1311 demonstrated durable efficacy in heavily pretreated metastatic castration-resistant prostate cancer ("mCRPC") patients with no new safety signals reported.
- A Phase 3 clinical trial ([NCT07365995](#)) to evaluate BNT324/DB-1311 compared to docetaxel in patients with mCRPC is expected to initiate in 2026.

mRNA Cancer Immunotherapies

BNT113 is an mRNA cancer immunotherapy candidate and based on BioNTech's fully owned, off-the-shelf FixVac platform, encoding the two oncoproteins E6 and E7 that are frequently found in human papillomavirus type 16 positive ("HPV16+") solid tumors.

- In December 2025, the FDA granted Fast Track designation to BNT113 for the treatment of patients with PD-L1+, HPV16+ HNSCC.
- Based on current event accrual projections, data are expected in 2026 from the first interim analysis of the Phase 3 part of the ongoing Phase 2/3 clinical trial (AHEAD-MERIT; [NCT04534205](#)) evaluating BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent or metastatic, PD-L1+, HPV16+ HNSCC.

Autogene cevumeran (BNT122/RO7198457) is an mRNA cancer immunotherapy candidate for individualized neoantigen-specific immunotherapy ("iNeST") that is being developed in collaboration with Genentech, Inc. ("Genentech"), a member of the Roche Group ("Roche").

- An update from the ongoing Phase 2 clinical trial in Stage II (high-risk)/Stage III circulating tumor DNA positive ("ctDNA+") adjuvant colorectal cancer ("CRC") is expected in early 2026. Data read-out from the final analysis of this trial has been updated from 2026 to 2027, given that events have accrued more slowly than projected.
- BioNTech and Roche, the sponsor of the trial, have decided to discontinue the Phase 2 clinical trial (IMcode004; [NCT06534983](#)) evaluating autogene cevumeran as an adjuvant treatment in combination with nivolumab compared to nivolumab alone in patients with high-risk muscle-invasive urothelial carcinoma due to the rapidly emerging treatment landscape and shifting standard of care. The companies will focus on advancing autogene cevumeran in the currently ongoing randomized Phase 2 clinical trials in adjuvant pancreatic ductal adenocarcinoma ("PDAC") and adjuvant CRC.

Expected 2026 Milestones

	Program	Modality	Trial Readout Phase	Indication
Late-Stage Trial Readouts	Trastuzumab pamirtecán³	ADC	Single-arm Phase 2	2L+ HER2-expressing endometrial cancer
			Phase 3 interim analysis	Chemo naïve HR+ HER2-low breast cancer
	Gotistobart²	Immunomodulator	Phase 3 interim analysis	2L+ sqNSCLC
			Phase 2	2L+ mCRPC
	BNT113	mRNA cancer immunotherapy	Phase 3 interim analysis	1L HPV16+ PD-L1+ HNSCC
	Pumitami¹	Immunomodulator	Phase 3 in China interim analysis	1L TNBC

Early-Stage Punitamig & ADC Trial Readouts	Punitamig ¹	Immunomodulator	Phase 2	1L NSCLC
			Phase 2	1L extensive-stage small-cell lung cancer ("ES-SCLC")
			Phase 2 in China	1L HCC
			Phase 2 in China	1L microsatellite stable colorectal cancer ("MSS-CRC")
	Punitamig ¹ + Trastuzumab pamirtecán (HER2-ADC) ³	Immunomodulator + ADC	Phase 1/2	Breast cancer
	Punitamig ¹ + BNT324/DB-1311 (B7H3-ADC) ³		Phase 1/2	Advanced solid tumors
	Punitamig ¹ + BNT325/DB-1305 (TROP2-ADC) ³		Phase 2	NSCLC/SCLC
	Punitamig ¹ + BNT326/YL202 (HER3-ADC) ⁴		Phase 2	TNBC
	Punitamig ¹ + BNT326/YL202 (HER3-ADC) ⁴		Phase 1/2	NSCLC
	BNT324/DB-1311 (B7H3-ADC) ³	ADC	Phase 1/2	2L+ mCRPC
Phase 3 Trial Initiations	Punitamig ¹	Immunomodulator	Phase 3	1L MSS-CRC
			Phase 3	1L HER2- PD-L1+ gastric cancer
			Phase 3	1L HNSCC
			Phase 3	NSCLC stage 3 unresectable
			Phase 3	1L NSCLC PD-L1 high
	BNT324 /DB-1311 (B7H3-ADC) ³	ADC	Phase 3	1L mCRPC
BLA Submission	Trastuzumab pamirtecán (HER2-ADC) ³	ADC	-	2L+ HER2-expressing endometrial cancer

Partnered with: 1. BMS; 2. OncoC4; 3. DualityBio; 4. MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink").

Upcoming Investor and Analyst Events

- BioNTech First Quarter 2026 Financial Results and Corporate Update: May 5, 2026
- BioNTech Annual General Meeting: May 15, 2026

Conference Call and Webcast Information

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, March 10, 2026, at 8:00 a.m. EDT (1:00 p.m. CET) to report its financial results and provide a corporate update for the fourth quarter and full year 2025.

To access the live conference call via telephone, please register [via this link](#). Once registered, dial-in numbers and a PIN number will be provided.

The slide presentation and audio of the webcast will be available [via this link](#).

Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page of the Investor section of the Company's website at www.BioNTech.com. A replay of the webcast will be made available shortly after the closing of the call and archived on the Company's website for 30 days following the call.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.

For more information, please visit www.BioNTech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech's leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; the terms of the preliminary discussions between BioNTech and the co-founders regarding the potential contribution of certain BioNTech assets to an independent company; BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or clinical trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech's expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational clinical trials, and the registrational potential of any clinical trial BioNTech may initiate; discussions with regulatory agencies; BioNTech's expectations with respect to intellectual property; the impact of BioNTech's collaboration and licensing agreements, including BioNTech's partnership with Bristol Myers Squibb; BioNTech's expectations with respect to developments in law, public policy, and

international trade; BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech's expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech's current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or annual booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech's other product candidates; the timing of and BioNTech's ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and market its product candidates, if approved; BioNTech's ability to manage its development and related expenses; regulatory and political developments; BioNTech's ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Annual Report on Form 20-F for the period ended December 31, 2025 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

CONTACTS

Investor Relations

Douglas Maffei, PhD
Investors@biontech.de

Media Relations

Jasmina Alatovic
Media@biontech.de

Abbreviation Overview

1L	First line
2L	Second line
adj.	Adjuvant
B7H3	B7 homologue B3
(MSS-)CRC	(Microsatellite stable-) colorectal cancer
ctDNA	Circulating tumor DNA
CTLA-4	Cytotoxic T-lymphocyte-associated protein
ES-SCLC	Extensive-stage small cell lung cancer
GBM	Glioblastoma
HCC	Hepatocellular carcinoma
HER2 (or HER3)	Human epidermal growth factor receptor 2 (or 3)
HNSCC	Head and neck squamous cell carcinoma
HPV16	Human papilloma virus 16
HR	Hormone receptor
IHC3+, 2+, 1+	Immunohistochemistry score 1+ (or 2+ or 3+)
ISH-positive	<i>In-situ</i> hybridization positive
mCRPC	Metastatic castration resistant prostate cancer
RCC	Renal cell carcinoma
(sq) NSCLC	(Squamous) non-small cell lung cancer
PDAC	Pancreatic ductal adenocarcinoma
PD-(L)1	Programmed cell death protein (death-ligand) 1
TNBC	Triple-negative breast cancer
TROP2	Trophoblast cell-surface antigen 2
VEGF-A	Vascular endothelial growth factor A

Consolidated Statements of Profit or Loss (IFRS Results)

	Three months ended December 31,		Years ended December 31,	
	2025 <i>(unaudited)</i>	2024 <i>(unaudited)</i>	2025	2024
<i>(in millions €, except per share data)</i>				
Revenues	907.4	1,190.0	2,869.9	2,751.1
Cost of sales	(333.3)	(243.5)	(641.8)	(541.3)
Research and development expenses	(505.4)	(611.8)	(2,104.9)	(2,254.2)
Sales and marketing expenses	(49.3)	(21.3)	(110.0)	(67.9)
General and administrative expenses	(168.6)	(110.8)	(514.4)	(531.1)
Other operating expenses	(208.0)	(91.6)	(1,088.3)	(811.5)
Other operating income	34.4	37.6	184.6	140.6
Operating profit / (loss)	(322.8)	148.6	(1,404.9)	(1,314.3)
Finance income	99.6	165.2	423.9	664.0
Finance expenses	(4.2)	(12.6)	(69.8)	(27.4)
Profit / (Loss) before tax	(227.4)	301.2	(1,050.8)	(677.7)
Income taxes	(77.6)	(41.7)	(85.3)	12.4
Net profit / (loss)	(305.0)	259.5	(1,136.1)	(665.3)
Earnings / (Loss) per share				
Basic earnings / (loss) per share	(1.25)	1.08	(4.70)	(2.77)
Diluted earnings / (loss) per share	(1.25)	1.08	(4.70)	(2.77)

Condensed Consolidated Statements of Profit or Loss (Adjusted Results)

Adjusted Results (non-IFRS measures) ¹	Three months ended December 31,		Years ended December 31,	
<i>(in millions €, except per share data)</i>	2025 <i>(unaudited)</i>	2024 <i>(unaudited)</i>	2025	2024
Adjusted cost of sales	(302.8)	(204.5)	(611.3)	(493.2)
Adjusted research and development expenses	(505.4)	(530.3)	(2,019.5)	(2,172.7)
Adjusted other operating expenses	(13.0)	(39.2)	(170.2)	(154.1)
Adjusted other operating income	34.4	37.6	169.6	140.6
Adjusted operating profit / (loss)	(97.3)	321.5	(385.9)	(527.3)
Adjusted profit / (loss) before tax	(1.9)	474.1	(31.8)	109.3
Adjusted net profit / (loss)²	(79.5)	432.4	(117.1)	121.7
Adjusted earnings / (loss) per share				
Adjusted basic earnings / (loss) per share	(0.33)	1.80	(0.48)	0.51
Adjusted diluted earnings / (loss) per share	(0.33)	1.79	(0.48)	0.50

¹ Certain adjusted results presented in this table are identical to our results under IFRS Accounting Standards. Reconciliation of all other adjusted results to our IFRS results can be found at the end of this press release and in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov.

² Tax effects are not considered as part of our non-IFRS adjustments

Consolidated Statements of Financial Position

<i>(in millions €)</i>	December 31, 2025	December 31, 2024
Assets		
Non-current assets		
Goodwill	367.9	380.6
Other intangible assets	1,606.0	790.4
Property, plant and equipment	1,080.9	935.3
Right-of-use assets	210.2	248.1
Contract assets	2.0	9.8
Other financial assets	2,554.2	1,254.0
Other non-financial assets	7.3	26.3
Deferred tax assets	13.5	81.7
Total non-current assets	5,842.0	3,726.2
Current assets		
Inventories	110.7	283.3
Trade and other receivables	924.2	1,463.9
Contract assets	8.1	10.0
Other financial assets	7,201.8	7,021.7
Other non-financial assets	173.8	212.7
Income tax assets	52.6	50.0
Cash and cash equivalents	7,675.4	9,761.9
Total current assets	16,146.6	18,803.5
Total assets	21,988.6	22,529.7
Equity and liabilities		
Equity		
Share capital	259.0	248.6
Capital reserve	2,473.3	1,398.6
Treasury shares	(7.7)	(8.6)
Retained earnings	17,961.9	19,098.0
Other reserves	(1,462.3)	(1,325.5)
Total equity	19,224.2	19,411.1
Non-current liabilities		
Lease liabilities, loans and borrowings	215.2	214.7
Other financial liabilities	94.9	46.9
Provisions	35.5	20.9
Contract liabilities	88.0	183.0
Other non-financial liabilities	104.2	87.5
Deferred tax liabilities	84.3	42.4
Total non-current liabilities	622.1	595.4
Current liabilities		
Lease liabilities, loans and borrowings	52.2	39.5
Trade payables and other payables	534.9	426.7
Other financial liabilities	351.7	1,443.4
Income tax liabilities	65.6	4.5
Provisions	145.3	144.8
Contract liabilities	754.9	294.9
Other non-financial liabilities	237.7	169.4
Total current liabilities	2,142.3	2,523.2
Total liabilities	2,764.4	3,118.6
Total equity and liabilities	21,988.6	22,529.7

Consolidated Statements of Cash Flows

<i>(in millions €)</i>	Three months ended December 31,		Years ended December 31,	
	2025 <i>(unaudited)</i>	2024 <i>(unaudited)</i>	2025	2024
Operating activities				
Net profit / (loss)	(305.0)	259.5	(1,136.1)	(665.3)
Income taxes	77.6	41.7	85.3	(12.4)
Profit / (Loss) before tax	(227.4)	301.2	(1,050.8)	(677.7)
Adjustments to reconcile loss before tax to net cash flows:				
Depreciation, amortization and impairment of property, plant, equipment, intangible assets and right-of-use assets	164.8	165.4	382.8	298.0
Share-based payment expenses	24.1	23.5	106.2	100.9
Net foreign exchange differences	(43.0)	(32.1)	(6.6)	(109.5)
(Gain) / Loss on disposal of property, plant and equipment	(0.8)	(0.1)	(2.5)	(0.3)
Finance income excluding foreign exchange differences	(99.1)	(149.7)	(423.9)	(648.5)
Finance expense excluding foreign exchange differences	4.3	12.6	21.4	27.4
Government grants	(19.5)	(4.7)	(63.0)	(31.5)
Other non-cash (income) / loss	600.4	—	585.4	—
Unrealized (gain) / loss on derivative instruments at fair value through profit or loss	2.5	3.9	(10.4)	4.6
Working capital adjustments:				
(Increase) / Decrease in trade and other receivables, contract assets and other assets	81.0	(879.9)	1,083.7	387.7
Decrease in inventories	116.2	19.9	177.9	74.5
(Decrease) / Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions	(424.6)	167.7	(723.8)	758.4
Interest received and realized gains from cash and cash equivalents	61.8	121.6	337.0	474.9
Interest paid and realized losses from cash and cash equivalents	(2.8)	(6.6)	(11.0)	(13.5)
Income tax received / (paid), net	40.5	(198.4)	3.8	(389.2)
Share-based payments	(6.0)	(10.9)	(25.3)	(154.5)
Government grants received	37.1	3.3	75.1	106.0
Net cash flows from operating activities	309.5	(463.3)	456.0	207.7
Investing activities				
Purchase of property, plant and equipment	(63.2)	(66.6)	(175.1)	(286.5)
Proceeds from sale of property, plant and equipment	0.6	0.7	4.5	1.2
Purchase of intangible assets	1.1	(24.5)	(573.9)	(165.8)
Acquisition of subsidiaries and businesses, net of cash acquired	264.8	—	186.3	—
Investment in other financial assets	(4,375.8)	(2,068.8)	(11,422.5)	(12,370.3)
Proceeds from maturity of other financial assets	1,446.9	2,765.9	9,512.2	10,740.2
Net cash flows used in investing activities	(2,725.6)	606.7	(2,468.5)	(2,081.2)
Financing activities				
Proceeds from loans and borrowings	6.7	—	6.7	—
Repayment of loans and borrowings	(8.6)	—	(18.0)	(2.3)
Payments related to lease liabilities	(10.4)	(7.3)	(39.6)	(43.6)
Transaction costs related to issuance of share capital	(2.0)	—	(2.0)	—
Net cash flows used in financing activities	(14.3)	(7.3)	(52.9)	(45.9)
Net decrease in cash and cash equivalents	(2,430.4)	136.1	(2,065.4)	(1,919.4)
Change in cash and cash equivalents resulting from exchange rate differences	1.4	13.6	(27.0)	14.8
Change in cash and cash equivalents resulting from other valuation effects	11.5	(12.4)	5.9	2.8
Cash and cash equivalents at the beginning of the period	10,092.9	9,624.6	9,761.9	11,663.7
Cash and cash equivalents as of December 31	7,675.4	9,761.9	7,675.4	9,761.9

Non-IFRS Reconciliation

Non-IFRS Reconciliation for the year ended December 31, 2025

<i>(in millions €, except per share data)</i>	non-IFRS adjustments					Adjusted Results
	IFRS Results	Expenses and income from legal proceedings	Impairment and reversal	Employee-related expenses from restructuring	Income from bargain purchase and income and expenses from divestiture related items	
Cost of sales	(641.8)	—	30.5	—	—	(611.3)
Research and development expenses	(2,104.9)	—	85.4	—	—	(2,019.5)
Other operating expenses	(1,088.3)	789.5	71.6	57.0	—	(170.2)
Other operating income	184.6	—	—	—	(15.0)	169.6
Operating loss	(1,404.9)	789.5	187.5	57.0	(15.0)	(385.9)
Loss before tax	(1,050.8)	789.5	187.5	57.0	(15.0)	(31.8)
Net loss¹	(1,136.1)	789.5	187.5	57.0	(15.0)	(117.1)
Loss per share						
Basic loss per share	(4.70)					(0.48)
Diluted loss per share	(4.70)					(0.48)

¹ Tax effects are not considered as part of our non-IFRS adjustments.

Non-IFRS Reconciliation for the three months ended December 31, 2025

<i>(in millions €, except per share data)</i>	non-IFRS adjustments					Adjusted Results
	IFRS Results <i>(unaudited)</i>	Expenses and income from legal proceedings	Impairment and reversal	Employee-related expenses from restructuring	Income from bargain purchase and income and expenses from divestiture related items	
Cost of sales	(333.3)	—	30.5	—	—	(302.8)
Other operating expenses	(208.0)	111.4	71.6	12.0	—	(13.0)
Operating loss	(322.8)	111.4	102.1	12.0	—	(97.3)
Loss before tax	(227.4)	111.4	102.1	12.0	—	(1.9)
Net loss¹	(305.0)	111.4	102.1	12.0	—	(79.5)
Loss per share						
Basic loss per share	(1.25)					(0.33)
Diluted loss per share	(1.25)					(0.33)

¹ Tax effects are not considered as part of our non-IFRS adjustments.

Non-IFRS Reconciliation for the year ended December 31, 2024

<i>(in millions €, except per share data)</i>	IFRS Results	non-IFRS adjustments				Adjusted Results
		Expenses and income from legal proceedings	Impairment and reversal	Employee-related expenses from restructuring	Income from bargain purchase and income and expenses from divestiture related items	
Cost of sales	(541.3)	—	48.1	—	—	(493.2)
Research and development expenses	(2,254.2)	—	81.5	—	—	(2,172.7)
Other operating expenses	(811.5)	657.4	—	—	—	(154.1)
Operating loss	(1,314.3)	657.4	129.6	—	—	(527.3)
Profit / (Loss) before tax	(677.7)	657.4	129.6	—	—	109.3
Net profit / (loss)¹	(665.3)	657.4	129.6	—	—	121.7
Earnings / (Loss) per share						
Basic earnings / (loss) per share	(2.77)					0.51
Diluted earnings / (loss) per share	(2.77)					0.50

¹ Tax effects are not considered as part of our non-IFRS adjustments.

Non-IFRS Reconciliation for the three months ended December 31, 2024

<i>(in millions €, except per share data)</i>	IFRS Results <i>(unaudited)</i>	non-IFRS adjustments				Adjusted Results
		Expenses and income from legal proceedings	Impairment and reversal	Employee-related expenses from restructuring	Income from bargain purchase and income and expenses from divestiture related items	
Cost of sales	(243.5)	—	39.0	—	—	(204.5)
Research and development expenses	(611.6)	—	81.5	—	—	(530.3)
Other operating expenses	(91.6)	52.4	—	—	—	(39.2)
Operating profit	148.6	52.4	120.5	—	—	321.5
Profit before tax	301.2	52.4	120.5	—	—	474.1
Net profit¹	269.5	52.4	120.5	—	—	432.4
Earnings per share						
Basic earnings per share	1.08					1.80
Diluted earnings per share	1.08					1.79

¹ Tax effects are not considered as part of our non-IFRS adjustments.

For the three months ended and the year ended December 31, 2023, our adjusted results were identical to our results under IFRS Accounting Standards.

4th Quarter & Full Year 2025 Financial Results & Corporate Update

March 10th, 2026



BIONTECH

This Slide Presentation Includes Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech's leadership and the transition of responsibilities at the Management Board; preliminary discussions between BioNTech and the co-founders regarding the potential contribution of certain BioNTech assets to an independent company; BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech's expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; discussions with regulatory agencies; BioNTech's expectations with respect to intellectual property; the impact of BioNTech's collaboration and licensing agreements, including BioNTech's partnership with BMS; BioNTech's expectations with respect to tariff policy; BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech's expectations of net profit / (loss). In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this presentation are based on BioNTech's current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: BioNTech's ability to successfully identify and recruit successors for the CEO and CMO positions; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech's other product candidates; the timing of and BioNTech's ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and its product candidates, if approved; BioNTech's ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech's ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Annual Report on Form 20-F for the period ended December 31, 2025, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise.

Furthermore, certain statements contained in this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and BioNTech's own internal estimates and research. While BioNTech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, any market data included in this presentation involves assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. While BioNTech believes its own internal research is reliable, such research has not been verified by any independent source. In addition, BioNTech is the owner of various trademarks, trade names and service marks that may appear in this presentation. Certain other trademarks, trade names and service marks appearing in this presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this presentation may be referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

An abbreviation directory of defined terms can be found at the end of the presentation.

1 Progress Highlights
Prof. Ugur Sahin, Co-founder & Chief Executive Officer

2 Oncology Execution
Prof. Özlem Türeci, Co-founder & Chief Medical Officer

3 Financial Performance
Ramón Zapata, Chief Financial Officer

BIONTECH



1 Progress Highlights

Ugur Sahin, Co-founder & Chief Executive Officer

BIONTECH



Translating Science into Survival
Building a Global Immunotherapy Powerhouse

BIONTECH

2025 and Recent Achievements: Strong Performance and Pipeline Momentum

COVID-19 Market Leadership 	Advanced Key Oncology Programs 	Executed Key Strategic Deals 	Strengthened Financial Position 
<ul style="list-style-type: none"> ✓ Launched variant-adapted COVID-19 vaccine ✓ Leading COVID-19 vaccine market share¹ 	<ul style="list-style-type: none"> ✓ Over 25 phase 2 & 3 oncology trials ongoing² ✓ 10 novel-combination trials ongoing with pumitamidg³ 	<ul style="list-style-type: none"> ✓ Strategic BMS partnership ✓ Acquired Biotheus ✓ Acquired CureVac 	<ul style="list-style-type: none"> ✓ Beat increased 2025 revenue guidance ✓ €17.2 billion in cash, cash equivalents and securities⁴
<small>1. Over 50%, including Italy, Spain, France, Germany, USA, Japan, Australia; 2. Includes Phase 2 or 3 trials for BNT111, BNT113, autogene cevumeran (partnered with Genentech, a member of the Roche Group), goltisobart (partnered with OncoC4), trastuzumab pamirtecian (partnered with DualityBio) and pumitamidg (partnered with Bristol Myers Squibb); 3. Partnered with Bristol Myers Squibb (BMS); 4. Cash and cash equivalents plus security investments as of December 31, 2025, reached €17,235.6 million, comprising €7,675.4 million in cash and cash equivalents, €7,138.5 million in security investments disclosed as current financial assets and €2,401.7 million in security investments disclosed as non-current financial assets.</small>			
6			



Oncology
Focus in
2026

1

Late-Stage Acceleration

Key late-stage data readouts expected for first wave of oncology assets

2

Combination Therapy Momentum

Novel-novel pumitamidg¹ combination data readouts expected

3

Modalities to Disease Areas

Transition to a focused disease area specific approach

¹ Partnered with Bristol Myers Squibb

7

BIONTECH

Building a Multi-Product Company by 2030

Targeting 18+ Late-Stage/Pivotal Trial Readouts Through 2030+ Informing Multiple Launch Opportunities

Tumor Type	Incidence ¹	Assets	Late-Stage/Pivotal Trials	Expected Data Readouts ²					
				2026	2027	2028	2029	2030+	
 Lung	1L NSCLC	400K	Pumitamidg ³	ROSETTA Lung-02					
	Stage III unresectable NSCLC	65K	Pumitamidg ³	ROSETTA Lung-201					
	1L NSCLC – PD-L1 ≥ 50%	60K	Pumitamidg ³	ROSETTA Lung-202					
	2L+ sqNSCLC ⁴	55K	Golistobart ⁴	PRESERVE-003					
 Breast	1L ES-SCLC	80k	Pumitamidg ³	ROSETTA Lung-01					
	1L TNBC – all comers	20k	Pumitamidg ³	Phase 3 in China					
	1L TNBC – CPS < 10	15k	Pumitamidg ³	ROSETTA Breast-01					
 Genitourinary	2L+ HR+ BC ¹ – HER2-low	55k	Trastuzumab-pamirtecan ⁵	DYNASTY Breast-02					
	1L RCC	40k	Pumitamidg ³	ROSETTA RCC-208 ⁷					
 Gastrointestinal	1L CRPC	110k	BNT324/DB-1311 ⁵	BNT324-03					
	1L MSS-CRC	230k	Pumitamidg ³	ROSETTA CRC-203					
	1L Gastric – HER2-neg, PD-L1+	40k	Pumitamidg ³	ROSETTA Gastric-204					
	1L HCC	25k	Pumitamidg ³	ROSETTA HCC-206 ⁷					
 Gynecologic	Adj. CRC – ctDNA+	70k	Autogene cevumeran ⁶	BNT122-01					
	Adj. PDAC	30k	Autogene cevumeran ⁶	IMCODE003					
	2L+ Endometrial ¹ – HER2-expressing	10k	Trastuzumab-pamirtecan ⁵	Single-arm Phase 2					
 Additional Tumors	Trastuzumab-pamirtecan ⁵			Fern-EC-01					
	1L HNSCC	160k	Pumitamidg ³	ROSETTA HNSCC-205					
	1L HNSCC – PD-L1 CPS ≥ 1, HPV16+	50k	BNT113	AHEAD-MERIT					

1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech's and its collaborators' product candidates, if approved. 2. Expected data readouts may be from interim or final analyses, and in some cases may not translate into commercial launches. Partnered with 3. Bristol Myers Squibb, 4. Oncoc4, 5. DualityBio, 6. Genentech, a member of the Roche group, 7. These are Phase 1/2 trials. The anticipated pivotal trials evaluating pumitamidg in these tumor types are expected to readout after 2030.

Strategic Focus to Maximize Value for Patients and Shareholders

Focus

Next Steps

BioNTech

Becoming a multi-product company by 2030

Sharpening focus on growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates

CEO and CMO transition by end of 2026

Executive search underway

New Company

Pioneering next-generation mRNA innovations with disruptive potential

BioNTech planning to contribute related rights and mRNA technologies in exchange for a minority stake

Signing of binding agreements expected by end of H1 2026

The information above is based on a non-binding letter of intent and is subject to the relevant parties entering into a final, definitive agreement.




2 Oncology Execution

Özlem Türeci, Co-founder &
Chief Medical Officer

BIONTECH

Multi-Modal Immunotherapy Oncology Strategy



1. Synergistic potential

Pumitamidg Strategy to Build a Proprietary IO Franchise

Establish

SCLC

- 1L Ph3 (Global)
- 2L Ph3 (China)



NSCLC

- 1L Ph2/3 (Global)
- 1L NSCLC Stage III unres. Ph3 (Global)
- 1L NSCLC PD-L1 ≥ 50% Ph3 (Global)



TNBC

- 1L Ph3 trial (Global)
- 1L Ph3 (China)



Expand

Registrational-Intent

- 1L Gastric Ph2/3 (Global)
- 1L CRC Ph2/3 (Global)
- 1L HNSCC Ph2/3 (Global)



Signal-Seeking

- 1L PDAC Ph2 (China)
- 1L GBM Ph2 (China)
- 1L RCC Ph1/2 (Global)
- 1L HCC Ph1/2 (Global)
- And others



Elevate

Combining with our ADCs targeting

- HER2
- TROP2
- B7H3
- HER3
- EGFR x HER3
- Novel targets

Exploring potential synergies with our IO agents

- EpCam x 4-1BB
- TIGIT x PVRIG
- mRNA cancer immunotherapy

Potential New Standards of Care
10+ novel-novel combinations

Broad Pan-Tumor Applicability With Standard-of-Care Chemotherapy
12+ trials exploring pumitamidg¹ in 10+ new indications

Foundational Registrations

Registrational trials with pumitamidg¹ ongoing in 3 high-impact tumors

¹ Partnered with Bristol Myers Squibb.

Pumitamidg Strategy to Build a Proprietary IO Franchise

Establish

SCLC

- 1L Ph3 (Global)
- 2L Ph3 (China)



NSCLC

- 1L Ph2/3 (Global)
- 1L NSCLC Stage III unres. Ph3 (Global)
- 1L NSCLC PD-L1 ≥ 50% Ph3 (Global)



TNBC

- 1L Ph3 trial (Global)
- 1L Ph3 (China)



Expand

Registrational-Intent

- 1L Gastric Ph2/3 (Global)
- 1L CRC Ph2/3 (Global)
- 1L HNSCC Ph2/3 (Global)



Signal-Seeking

- 1L PDAC Ph2 (China)
- 1L GBM Ph2 (China)
- 1L RCC Ph1/2 (Global)
- 1L HCC Ph1/2 (Global)
- And others



Elevate

- Combining with our ADCs targeting
 - HER2
 - TROP2
 - B7H3
 - HER3
 - EGFR x HER3
 - Novel targets
- Exploring potential synergies with our IO agents
 - EpCam x 4-1BB
 - TIGIT x PVRIG
 - mRNA cancer immunotherapy

Potential New Standards of Care
10+ novel-novel combinations

Broad Pan-Tumor Applicability With Standard-of-Care Chemotherapy
12+ trials exploring pumitamidg¹ in 10+ new indications

Foundational Registrations

Registrational trials with pumitamidg¹ ongoing in 3 high-impact tumors

¹ Partnered with Bristol Myers Squibb.

Establishing & Expanding Punitamig¹ in Combination with Current SoC

		Phase 2		Phase 3	
		Status	Dose Selection	Global Initiation	Primary Completion
SCLC	1L	✓	✓	✓	2028
TNBC	1L	✓	✓	✓	2029
	1L		✓	✓	2029
NSCLC	Stg. III unresectable	✓	✓	2026	2030+
	1L PD-L1 ≥50%		✓	2026	2030+
CRC	1L	Ongoing	2026	2026	2030
Gastric	1L	Ongoing	2026	2026	2030
HNSCC	1L	2026	2026	2026	2030+
HCC	1L	Ongoing	Phase 2 trials to inform pivotal development		
RCC	1L	Ongoing			
GBM	1L	Ongoing in China			
PDAC	1L	Ongoing in China			

¹ Partnered with Bristol Myers Squibb.

Expanding BioNTech's Focus on Lung Cancer to Maximize Pipeline Potential

	Resectable	Stage III Unresectable	1L metastatic	2L+ metastatic
Incidence¹	220K	65K	400K	230K
NSCLC	Pumitamid ² + chemo IIT ⁶	Pumitamid ² ROSETTA LUNG-201	Pumitamid ² ROSETTA LUNG-202	Gotistobart ³ PRESERVE-003 (sq)
	Pumitamid ² + FixVac LuCa-MERIT-1		Pumitamid ² + chemo ROSETTA LUNG-02	FixVac + Gotistobart ³ /ADCs LuCa-MERIT-1
Incidence¹			80K	35K
SCLC			Pumitamid ² + ADCs BNT324 ⁴ , BNT325 ⁴ , BNT326 ⁵	ADC monos BNT324 ⁴ , BNT325 ⁴ , BNT326 ⁵
			Pumitamid ² + chemo ROSETTA LUNG-01	ADC mono BNT324 ⁴
			Pumitamid ² + ADC (BNT324 ⁴)	

■ Next generation IO ■ Targeted therapy ■ mRNA immunotherapy — Registrational trials --- Ph1/2 PoC trials

1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026. Incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech's and its collaborators' product candidates, if approved. Partnered with: 2. Bristol Myers Squibb; 3. Oncoc4; 4. DualityBio (BNT324/DB-1311, BNT325/DB-1305); 5. MediLink (BNT326/YL202); 6. Being conducted in China.

Executing a Parallel Three-Wave Strategy to Build a Proprietary IO Franchise

Establish

SCLC

- 1L Ph3 (Global)
- 2L Ph3 (China)



NSCLC

- 1L Ph2/3 (Global)
- 1L NSCLC St III unres. Ph3 (Global)
- 1L NSCLC PD-L1 \geq 50% Ph3 (Global)



TNBC

- 1L Ph3 trial (Global)
- 1L Ph3 (China)



Expand

Registrational-Intent

- 1L Gastric Ph2/3 (Global)
- 1L CRC Ph2/3 (Global)
- 1L HNSCC Ph2/3 (Global)



Signal-Seeking

- 1L PDAC Ph2 (China)
- 1L GBM Ph2 (China)
- 1L RCC Ph1/2 (Global)
- 1L HCC Ph1/2 (Global)
- And others



Elevate

Combining with our ADCs targeting

- HER2
- TROP2
- B7H3
- HER3
- EGFR x HER3
- Novel targets

Exploring potential synergies with our IO agents

- EpCam x 4-1BB
- TIGIT x PVRIG
- mRNA cancer immunotherapy

Potential New Standards of Care
10+ novel-novel combinations

Broad Pan-Tumor Applicability With Standard-of-Care Chemotherapy
12+ trials exploring pumitamidg¹ in 10+ new indications

Foundational Registrations

Registrational trials with pumitamidg¹ ongoing in 3 high-impact tumors

¹ Partnered with Bristol Myers Squibb.

Single-Agent Activity of ADCs Being Explored Across Indications

Advancing Single-Agent Towards Commercial Stage

T-Pam¹ BC Phase 3 fully enrolled with interim data expected in late 2026

T-Pam¹ EC Phase 2 fully enrolled with data expected in 2026, confirmatory Phase 3 ongoing

BNT324/DB-1311¹ Phase 3 in 1L mCRPC to start in 2026

BNT326/YL202² Phase 2 in 2L+ HER2-low/-null BC presented at SABCS 2025

■ Registrational trial
■ Phase 1/2 trial

	Lung			Breast		Genitourinary		Gastrointestinal				Gynecologic			Additional Tumors		
	NSCLC AGA-	NSCLC EGFRm	SCLC	TNBC	HR+/HER2- BC	RCC	Prostate	GC/GEJ	CRC	PDAC	HCC	Endometrial	Cervical	OC	GBM	HNSCC	Melanoma
T-Pam ¹					■							■					
BNT324/DB-1311 ¹	■	■	■				■				■		■			■	
BNT325/DB-1305 ¹	■	■		■	■								■				
BNT326/YL202 ²								■	■				■			■	

Partnered with 1. DualityBio; 2. MedLink.

Novel Combinations to Expand Pumitamid Opportunity Across Cancer Types

Building Foundations for Registrational Combinations

10 novel-novel combination trials ongoing with pumitamid¹

Generating clinical data from pumitamid¹ combined with ADCs

Multiple data readouts expected in 2026

■ Registrational trial
■ Phase 1/2 trial

	Lung			Breast		Genitourinary		Gastrointestinal				Gynecologic		Additional Tumors		
	NSCLC/AGA-	NSCLC/EGFRm	SCLC	TNBC	HR+/HER2-BC	RCC	Prostate	GC/GEJ	CRC	PDAC	HCC	Cervical	OC	GBM	HNSCC	Melanoma
Pumitamid¹ +																
SoC																
T-Pam ²																
BNT324/DB-1311 ²																
BNT325/DB-1305 ²																
BNT326/YL202 ³																

Partnered with 1. Bristol Myers Squibb; 2. DualityBio; 3. MediLink.

Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios

Autogene cevumeran ¹		BNT113	BNT116 ²
Adjuvant		1L	Multiple settings
CRC Phase 2	PDAC Phase 2	HPV16+ PD-L1 CPS ≥1 HNSCC Phase 2/3	NSCLC Phase 1 & 2
Monotherapy	+ Atezolizumab + mFOLFIRINOX	+ Pembrolizumab	Mono & combo with IO & ADCs
<ul style="list-style-type: none"> Recruitment ongoing Data presented from epi sub-study at ASCO 2024 and from biomarker sub-study at ESMO-GI 2024 	<ul style="list-style-type: none"> Recruitment ongoing Data from Phase 1 trial published: Rojas et al., Nature 2023; Sethna et al., Nature 2025 	<ul style="list-style-type: none"> Recruitment ongoing Trial updated to Phase 2/3 	<ul style="list-style-type: none"> Recruitment completed in Phase 2 in 1L NSCLC² Data presented at SITC 2023, AACR 2024 and SITC 2024 Data in frail patients presented at AACR 2025 Data in patients after CRT presented at WCLC 2025
Phase 2 final analysis expected in 2027	Primary Completion Date in 2031	Phase 3 interim analysis expected in 2026	
Individualized Immunotherapy – iNeST ¹		Off-the-shelf Immunotherapy – FixVac	

Partnered with: 1. Genentech, a member of the Roche Group; 2. In collaboration with Regeneron.

Catalyst-Rich Year Ahead with Multiple Expected 2026 Milestones

	Program	Trial Readout Phase	Indication
Late-Stage Trial Readouts	Trastuzumab-pamirtecan ³	Single arm Phase 2	2L+ HER2-expressing endometrial cancer
		Phase 3 ⁵ interim analysis	Chemo naive HR+ HER2-low breast cancer
	Gotitobart ²	Phase 3 ⁵ interim analysis	2L+ sqNSCLC
		Phase 2	2L+ mCRPC
Early-Stage Pumitamid & ADC Trial Readouts	BNT113	Phase 3 ⁵ interim analysis	HPV16+ PD-L1+ HNSCC
	Pumitamid ¹	Phase 3 ⁵ in China interim analysis	1L TNBC
		Phase 2	1L NSCLC
	Pumitamid ¹	Phase 2	1L ES-SCLC
		Phase 2 in China	1L HCC
	Pumitamid ¹	Phase 2 in China	1L MSS-CRC
		Pumitamid ¹ + Trastuzumab-pamirtecan ³	Phase 1/2
	Pumitamid ¹ + BNT324/DB-1311 ³	Phase 1/2	Advanced solid tumors
	Pumitamid ¹ + BNT325/DB-1305 ³	Phase 2	NSCLC/SCLC
	Pumitamid ¹ + BNT326/YL202 ⁴	Phase 1/2	TNBC
BNT324/DB-1311 ³	Phase 1/2	NSCLC	
Phase 3 Trial Initiations	Pumitamid ¹	Phase 3 ⁵	2L+ mCRPC
			1L MSS-CRC
	BNT324/DB-1311 ³	Phase 3	1L HER2- PD-L1+ gastric cancer 1L HNSCC 1L NSCLC – PD-L1 ≥ 50% Stage III unresectable NSCLC
BLA Submission	Trastuzumab-pamirtecan ³	-	1L mCRPC 2L+ HER2-expressing endometrial cancer

Data from the final analysis of the autogene cevumeran study BNT122-01 were previously expected in 2026. Given events have accrued more slowly than projected, the data from the final analysis are now expected in 2027. Same data readouts may be event-driven and subject to change based on actual event accrual rates. Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. DualityBio; 4. MedLink; 5. Pivotal trial.



3 Financial Performance

Ramón Zapata,
Chief Financial Officer

BIONTECH

Full Year 2025 Financial Results Compared to Guidance

In € millions	FY 2025 IFRS Results ¹	FY 2025 IFRS Guidance
Total Revenues	2,870	2,600 – 2,800
R&D Expenses	2,105	2,000 – 2,200
SG&A Expenses	624	550 – 650
Capital Expenditures for Operating Activities	198	200 – 250

1. Numbers have been rounded. More information can be found in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov.

Full Year 2025 Financial Results

In € millions except per share data ¹	FY 2025		FY 2024	
	IFRS Results	Adjusted Results ²	IFRS Results	Adjusted Results ²
Revenues	2,870	2,870	2,751	2,751
Cost of sales	(642)	(611)	(541)	(493)
Research and development expenses	(2,105)	(2,020)	(2,254)	(2,173)
Sales, marketing, general and administrative expenses	(624)	(624)	(599)	(599)
Other operating result	(904)	(1)	(671)	(14)
Operating loss	(1,405)	(386)	(1,314)	(527)
Net profit / (loss)	(1,136)	(117)	(665)	122
Diluted earnings / (loss) per share	(4.70)	(0.48)	(2.77)	0.50

Balance Sheet as of December 31, 2025 – Cash and cash equivalents plus security investments³ €17.2 bn

1. All numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS") or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Cash and cash equivalents plus security investments as of December 31, 2025, reached €17,235.6 million, comprising €7,675.4 million in cash and cash equivalents, €7,158.5 million in current security investments disclosed as financial assets and €2,401.7 million in non-current security investments disclosed as financial assets.

Fourth Quarter 2025 Financial Results

In € millions except per share data ¹	4Q 2025		4Q 2024	
	IFRS Results	Adjusted Results ²	IFRS Results	Adjusted Results ²
Revenues	907	907	1,190	1,190
Cost of sales	(333)	(302)	(244)	(205)
Research and development expenses	(505)	(505)	(612)	(530)
Sales, marketing, general and administrative expenses	(218)	(218)	(132)	(132)
Other operating result	(174)	21	(54)	(2)
Operating profit / (loss)	(323)	(97)	149	322
Net profit / (loss)	(305)	(80)	260	432
Diluted earnings / (loss) per share	(1.25)	(0.33)	1.08	1.79

Balance Sheet as of December 31, 2025 – Cash and cash equivalents plus security investments³ €17.2 bn

1. All numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS") or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Cash and cash equivalents plus security investments as of December 31, 2025, reached €17,235.6 million, comprising €7,675.4 million in cash and cash equivalents, €7,158.5 million in current security investments disclosed as financial assets and €2,401.7 million in non-current security investments disclosed as financial assets.

Full Year 2026 Financial Guidance¹

In € millions	FY 2026 non-IFRS Guidance
Total Revenues	2,000 – 2,300
Adjusted R&D Expenses	2,200 – 2,500
Adjusted SG&A Expenses	700 – 800

Revenue Guidance Considerations

- Competitive market dynamics in the United States
- Begin managing transition of multi-year contracts in Europe, and specifically in Germany where BioNTech recognizes direct sales
- Stable revenues from the collaboration with BMS, from a pandemic preparedness contract with the German government, and from the BioNTech Group service businesses
- No one-time revenue from Pfizer opt-out from further development of shingles program

1. Excludes risks that are not yet known and/or quantifiable and related activities. It includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions ("M&A") transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech's Report on Form 20-F for the year ended December 31, 2023 filed on March 10, 2024, which is available at www.sec.gov.

2025



**Advanced Strategy,
Matured Pipeline and
De-risked Development**

Progressed key programs into pivotal stage, established partnership with BMS, fortified balance sheet with €17.2 billion in cash¹ to fund our pipeline

2026 – 2029

**Drive Oncology
Execution at
Scale and Speed**

Advance combination therapy studies, accelerate pivotal trial execution, build indication-specific oncology portfolios and execute oncology launches

2030

**Diversified Multi-
Product Company**

Build a diversified, multi-product global immunotherapy powerhouse addressing high unmet medical need of cancer patients worldwide

1. Preliminary, unaudited figure; consists of cash, cash equivalents and security investments, as of December 31, 2025.

— Thank you



Appendix

BIONTECH

Reconciliation of Adjusted to IFRS Results – FY 2025 & 2024 Financial Results

In € millions except per share data ¹	FY 2025			FY 2024		
	IFRS Results	Non-IFRS Adjustments	Adjusted Results ²	IFRS Results	Non-IFRS Adjustments	Adjusted Results ²
Revenues	2,870	-	2,870	2,751	-	2,751
Cost of sales	(642)	31	(611)	(541)	48	(493)
Research and development expenses	(2,105)	85	(2,020)	(2,254)	81	(2,173)
Sales, marketing, general and administrative expenses	(624)	-	(624)	(599)	-	(599)
Other operating result	(904)	903	(1)	(671)	657	(14)
Operating loss	(1,405)	1,019	(386)	(1,314)	786	(527)
Net profit / (loss)³	(1,136)	1,019	(117)	(665)	786	122
Basic earnings / (loss) per share	(4.70)		(0.48)	(2.77)		0.51
Diluted earnings / (loss) per share	(4.70)		(0.48)	(2.77)		0.50

¹ All numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. ² In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS") or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. ³ Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

Reconciliation of Adjusted to IFRS Results – 4Q 2025 & 2024 Financial Results

In € millions except per share data ¹	4Q 2025			4Q 2024		
	IFRS Results	Non-IFRS Adjustments	Adjusted Results ²	IFRS Results	Non-IFRS Adjustments	Adjusted Results ²
Revenues	907	-	907	1,190	-	1,190
Cost of sales	(333)	31	(302)	(244)	39	(205)
Research and development expenses	(505)	-	(505)	(612)	82	(530)
Sales, marketing, general and administrative expenses	(218)	-	(218)	(132)	-	(132)
Other operating result	(174)	195	21	(54)	52	(2)
Operating profit / (loss)	(323)	226	(97)	149	173	322
Net profit / (loss)³	(305)	226	(80)	260	173	432
Basic earnings / (loss) per share	(1.25)		(0.33)	1.08		1.80
Diluted earnings / (loss) per share	(1.25)		(0.33)	1.08		1.79

¹ All numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. ² In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS") or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. ³ Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

BioNTech's Oncology Pipeline

Phase 1	Phase 1/2	Phase 2	Phase 2/3	Phase 3				
BNT116 Adv. NSCLC	BNT324/DB-1311 ¹ Multiple solid tumors	Pumitamidg ¹ + BNT314/GEN1059 ⁶ Met. CRC ²	Autogene cevumeran ² Adj. CRC	Pumitamidg ¹ 2L ES-SCLC ³	Pumitamidg ¹ or BNT325/DB-1305 + BNT324/DB-1311 ¹ ³ Multiple solid tumors ⁹	BNT113 1L HPV16+ HNSCC	BNT324/ DB-1311 ¹ ³ Met. CRPC	Trastuzumab pamirtecán ³ Met. BC
BNT211 Multiple solid tumors	BNT325/DB-1305 ³ Multiple solid tumors	Pumitamidg ¹ + BNT3212 Multiple solid tumors	Autogene cevumeran ² Adj. PDAC	Pumitamidg ¹ 2L+ EGFRm NSCLC ³		Pumitamidg ¹ 1L met. CRC	Gotitobart ⁴ Met. NSCLC	Trastuzumab pamirtecán ³ 2L EC
BNT314/GEN1059 ⁶ Multiple solid tumors	BNT329 Multiple solid tumors	Pumitamidg ¹ + BNT3213 1L HCC ³	BNT116 ⁷ 1L adv. NSCLC	Pumitamidg ¹ 2L Glioblastoma ⁸		Pumitamidg ¹ 1L met. Gastric	Pumitamidg ¹ 1L ES-SCLC	
BNT317 Multiple solid tumors	Gotitobart ⁴ Met. CRPC	Pumitamidg ¹ + BNT324/DB-1311 ¹ Adv./met. NSCLC and SCLC ³	BNT326/YL202 ⁵ Multiple solid tumors ⁹	Pumitamidg ¹ 1L HCC ³		Pumitamidg ¹ 1L HNSCC	Pumitamidg ¹ 1L adv. NSCLC	
BNT326/YL202 ⁵ Multiple solid tumors	Gotitobart ⁴ Multiple solid tumors	Pumitamidg ¹ + BNT325/DB-1305 ³ Multiple solid tumors ⁹	BNT326/YL202 ⁵ Adv./met. BC ³	Pumitamidg ¹ 1L MPM ⁶		Pumitamidg ¹ 1L NSCLC	Pumitamidg ¹ Unresectable Stage III NSCLC	
	Pumitamidg ¹ Multiple solid tumors	Pumitamidg ¹ + BNT326/YL202 ⁵ Multiple solid tumors	Gotitobart ⁴ PROC	Pumitamidg ¹ 2L NEN ⁶			Pumitamidg ¹ 2L SCLC ³	
	Pumitamidg ¹ 1L adv. HCC	Pumitamidg ¹ + BNT326/YL202 ⁵ Adv. NSCLC	Pumitamidg ¹ 1L met. CRC ²	Pumitamidg ¹ 2L adv./met. NSCLC			Pumitamidg ¹ 1L adv./met. TNBC	
	Pumitamidg ¹ Adv. RCC	Pumitamidg ¹ + Trastuzumab pamirtecán ³ Adv./met. BC ³	Pumitamidg ¹ 1L ES-SCLC ³	Pumitamidg ¹ 1L met. PDAC ⁴			Pumitamidg ¹ 1L adv./met. TNBC ⁴	
	Pumitamidg ¹ 1L adv./met. TNBC ⁴	Trastuzumab pamirtecán ³ Multiple solid tumors	Pumitamidg ¹ 1L/2L+ ES-SCLC	Pumitamidg ¹ 1L/2L adv./met. TNBC				

■ Next generation immunomodulator
 ■ Targeted therapy
 ■ mRNA immunotherapy
 ■ Novel-novel combination

Partnered with: 1. Bristol Myers Squibb; 2. Genentech, a member of the Roche Group; 3. DualityBio; 4. OncoC4; 5. MediLink; 6. Genmab; 7. In collaboration with Regeneron; 8. Trial ongoing in China only; 9. Trial is currently being conducted by or on behalf of BioNTech. Bristol Myers Squibb holds co-exclusive rights to pumitamidg.

BioNTech's Infectious Diseases Pipeline

Phase 1	Phase 1/2	Phase 2	Commercial
BNT163 ¹ HSV	BNT162 + BNT161 ² COVID-19 – Influenza combination	BNT166 ⁵ Mpox	BNT162 ^{2,3} COVID-19
BNT351 HIV	BNT164 ⁴ Tuberculosis		
	BNT165 Malaria		
	BNT166 ⁵ Mpox		

■ Antibody
 ■ mRNA

Partnered with: 1. University of Pennsylvania; 2. Pfizer; 3. Fosun Pharma; 4. Funded by the Gates Foundation; 5. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

Abbreviation Directory

4-1BB	CD137	G7 markets	Canada, France, Germany, Italy, Japan, GB, USA	(sq) NSCLC	(squamous) Non-small cell lung cancer
n L	<i>nth</i> line	GB	Great Britain	OC	Ovarian cancer
AACR	American Association for Cancer Research	GBM	Glioblastoma	PCD	Projected Commercialization Date
ADC	Antibody-drug conjugate	GC/GEJ	Gastric/Gastro-esophageal junction cancer	PD-(L)1	Programmed cell death protein (ligand) 1
adj.	Adjuvant	HCC	Hepatocellular carcinoma	PDAC	Pancreatic ductal adenocarcinoma
adv.	Advanced	HER2 (or 3)	Human epidermal growth factor receptor 2 (or 3)	PoC	Proof of concept
AGA	Actionable oncogenic alteration	HIV	Human immunodeficiency virus	PROC	Platinum-resistant ovarian cancer
ASCO	American Society of Clinical Oncology	HNC	Head and neck cancer	PVRIG	Poliovirus receptor-related immunoglobulin
B7-H3	B7 Homolog 3	HNSCC	Head and neck squamous cell carcinoma	R&D	Research and development
BC	Breast cancer	HPV	Human papilloma virus	(ncc/cc)RCC	((non-)clear cell) Renal cell carcinoma
BLA	Biologics License Applications	HR	Hormone receptor	SABCS	San Antonio Breast Cancer Symposium
BMS	Bristol Myers Squibb	HSV	Herpes simplex virus	(ES)SCLC	(Extensive stage) small cell lung cancer
CPS	Combined positive score	IFRS	International financial reporting standards	SEC	U.S. Securities and Exchange Commission
CRC	Colorectal cancer	IIT	Investigator initiated trial	SG&A	Selling, general and administrative expenses
(m)CRPC	(met.) Castration resistant prostate cancer	iNeST	Individualized NeoAntigen-Specific Therapy	SITC	Society of Immunotherapy of Cancer
CRT	Chemoradiation therapy	IO	Immuno-oncology	SoC	Standard of care
ctDNA	Circulating tumor DNA	M&A	Merger and acquisitions	TIGIT	T cell immunoreceptor with Ig and ITIM domains
EC	Endometrial cancer	met.	Metastatic	TM	Trademark
EGFR(m)	(mutated) Epidermal growth factor receptor	MIUC	Muscle-invasive urothelial carcinoma	TNBC	Triple-negative breast cancer
EpCAM	Epithelial cell adhesion molecule	MPM	Malignant pleural mesothelioma	T-Pam	Trastuzumab pamirtecan
ESMO	European Society for Medical Oncology	Mpox	Monkeypox	TROP2	Trophoblast cell-surface antigen 2
EU4(5)	Germany, France, Italy, Spain, (UK)	mRNA	Messenger ribonucleic acid	U.S.	United States
FixVac	Fixed Antigen Vaccine	MSS	Microsatellite stability	UK	United Kingdom
FY	Fiscal year	NEN	Neuroendocrine neoplasm	WCLC	World Conference of Lung Cancer

